| Abstrakt: |
Researchers from the Pharmaceuticals and Medical Devices Agency in Japan conducted a study to evaluate the risk of neutropenia in psoriasis patients prescribed anti-IL-23 antibodies compared to anti-IL-17 antibodies or adalimumab. The study included 287 patients on anti-IL-23 antibodies, 189 patients on anti-IL-17 antibodies, 293 patients on adalimumab, and 540 patients on apremilast. The findings indicated no clear increase in the risk of neutropenia with anti-IL-23 antibodies. [Extracted from the article] |
